clinical trial · NCT06955741
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
Bristol-Myers Squibb·phase1·completed·n = 46
Healthy VolunteerBMS-986446 IVBMS-986446 SCAcetaminophenLoratadine
brief summary
The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants
started
May 5, 2025
primary completion
Sep 11, 2025
completion
Sep 11, 2025
last updated
Oct 1, 2025
official title
A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol